AbbVie Inc. (ABBV) News
Filter ABBV News Items
ABBV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ABBV News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest ABBV News From Around the Web
Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.
AbbVie (NYSE:ABBV) Has A Pretty Healthy Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the... |
3 Incredible Dividend Stocks to Buy in 2025These wildly successful companies are poised to keep your dividend portfolio healthy in 2025 and beyond. |
Top Stock Movers Now: Constellation Brands, Allstate, Delta Air Lines, and MoreU.S. equities slumped at midday after the December jobs report came in higher than anticipated, putting more Federal Reserve rate cuts in doubt. |
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia DrugAbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. |
AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel DrugAbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment . |
Pfizer’s PD-1 drug succeeds; AbbVie writes down $3.5B in Cerevel assetsSasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire. |
AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceAbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time. |
How to Find Strong Medical Stocks Slated for Positive Earnings SurprisesInvestors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. |
AbbVie (ABBV) Stock Moves -0.32%: What You Should KnowIn the most recent trading session, AbbVie (ABBV) closed at $179.53, indicating a -0.32% shift from the previous trading day. |
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |